MedTrace Logo

Effectiveness and Safety of Nexpowder as an Endoscopic Hemostatic Treatment

NCT05884931 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2024-02-23

No results posted yet for this study

Summary

In patients who show signs of bleeding and bleeding after polypectomy such as EMR and ESD for polyps with a diameter of 2 cm or more in the lower gastrointestinal tract, the effectiveness and safety of Nexpowder as an endoscopic hemostatic treatment are confirmed.

Conditions

  • GastroIntestinal Bleeding

Interventions

DEVICE

Nexpowder

Hemostatic powder for endoscopy after colonoscopy polypectomy

PROCEDURE

Conventional Treatment

Standard hemostatic procedure

Sponsors & Collaborators

  • Next Biomedical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Kibae Kim, Ph.D. · Chungbuk National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-18
Primary Completion
2023-12-01
Completion
2023-12-29

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05884931 on ClinicalTrials.gov